Unknown PHASE1 INTERVENTIONAL 1-arm NCT01772732

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions Non-small Cell Lung Cancer

Interventions Simotinib Hydrochloride

Updated 6 times since 2017 Last updated: Apr 7, 2015 Started: Dec 31, 2012 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01772732, this PHASE1 trial focuses on Non-small Cell Lung Cancer and remains ongoing. Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
May 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Recruiting PHASE1

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Data source: Jiangsu Simcere Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China